Autres langues Torii Pharmaceutical Co., Ltd.

Actions

4551

JP3635800000

Temps Différé Japan Exchange Autres places de cotation 06:56:47 08/05/2024			Varia. 5j.	Varia. 1 janv.
3 980 ^JPY	-0,13%		+0,25%	+12,10%

13/02	LIM Advisors retire partiellement sa proposition d'actionnaire	CI
09/02	Torii Pharmaceuticals s'oppose à la proposition des actionnaires	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

LIM Advisors Partially Withdraws Shareholder Proposal	13/02
Torii Pharmaceuticals Opposes Shareholder Proposal	09/02
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	18/12
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	18/12
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	15/12
Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	13/12
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	12/12
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	12/12
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	30/11
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	31/10/23
Torii Pharmaceutical - JT Files New Drug Application of JTE-061 Cream, Aryl hydrocarbon Receptor agonist, for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	18/09/23
Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	15/09/23
Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	28/04/23
Torii Pharmaceutical Announces Voting Results	30/03/23
Torii Pharmaceutical : Views on Report from ISS, a Proxy Advisory Firm, On Proposals for ’s General Meeting of Shareholders	16/03/23
Torii Pharmaceutical : Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal	17/02/23
Torii has announced Medium-Term Management Plan 2023-2025	13/02/23
Torii Pharmaceutical : has announced Medium-Term Management Plan 2023-2025	10/02/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Torii Pharmaceutical Co., Ltd.

Actions

4551

JP3635800000

Autres langues

Filtres